Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice

PHASE3TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Arm Spasticity
Interventions
BIOLOGICAL

Botulinum toxin type A

Trial Locations (23)

2400

Bispebjerg Hospital, København NV

2600

Glostrup Hospital, Glostrup Municipality

4000

Roskilde Hospital, Roskilde

5021

Haukeland University Hospital, Bergen

7100

Vejle Hospital, Vejle

8450

Regionshospitalet Hammel, Hammel

8800

Regionshopsitalet Viborg, Viborg

9000

Aalborg Sygehus Nord, Aalborg

18288

Danderyds Hospital,, Stockholm

27133

Ystad Lasarett, Ystad

30185

Hallands Sjukhus, Neurology Clinic, Halmstad

40503

Central Hospital of Central Finland, Jyväskylä

61185

Nyköpings Lasarett,, Nyköping

62184

Rehabilitation Center Gotland, Visby

80210

North Karelia Central Hospital, Joensuu

83102

Östersunds Rehabilitation Center, Östersund

87182

Sundsvall-Härnösand, Rehabilitation Medicine, Härnösand

91831

Neurorehab Sävar, Sävar

, 3700

Sykehuset Telemark HF, Skien

631-88

Mälarsjukhuset MSE, Eskilstuna

Unknown

Sahlgrenska University Hospital, Gothenburg

891 89

Örnsköldsviks Sjukhus, Neurology Clinic, Örnsköldsvik

114 33

Neurology Clinic Stockholm, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT01682148 - Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice | Biotech Hunter | Biotech Hunter